神经梅毒发病的危险因素及预测因素研究进展

doi:10.35541/cjd.20200191

摘要/Abstract

摘要： 【摘要】神经梅毒是梅毒螺旋体侵犯神经系统而导致的较严重的临床阶段，伴或不伴HIV感染的梅毒患者发生神经梅毒的危险因素及预测因素有所不同。HIV阴性梅毒患者发生神经梅毒的危险因素主要包括性别、年龄、梅毒感染阶段、治疗情况等；预测因素包括血清学滴度、脑脊液一些指标的变化及是否伴有神经系统或眼科症状等。HIV病毒载量及CD4+ T细胞计数、抗反转录病毒治疗情况是HIV阳性梅毒患者发生神经梅毒的主要预测及危险因素。

关键词: 神经梅毒, 危险因素, HIV, 梅毒血清诊断, 预测因素

Abstract: 【Abstract】 Neurosyphilis is a serious clinical stage of syphilis caused by Treponema pallidum invading the nervous system, and risk and predictive factors of neurosyphilis are different between syphilis patients with and without HIV infection. The risk factors for neurosyphilis in HIV-negative patients with syphilis mainly include gender, age, clinical stage of syphilis, treatment, etc.; the predictive factors include serological titers, changes in some indicators of cerebrospinal fluid, neurological or ophthalmic symptoms. HIV viral load, CD4+ T cell counts and antiretroviral treatment are the main predictors and risk factors for neurosyphilis in HIV-positive patients with syphilis.

Key words: Neurosyphilis, Risk factors, HIV, Syphilis serodiagnosis, Predictive factors

中图分类号:

李可王千秋龙福泉. 神经梅毒发病的危险因素及预测因素研究进展[J]. 中华皮肤科杂志, 2021, 54(5): 459-462.doi:10.35541/cjd.20200191

Li Ke, Wang Qianqiu, Long Fuquan. Risk factors and predictors of neurosyphilis[J]. Chinese Journal of Dermatology, 2021, 54(5): 459-462.doi:10.35541/cjd.20200191

参考文献 34

［1］	Daey Ouwens IM, Koedijk FD, Fiolet AT, et al. Neurosyphilis in the mixed urban⁃rural community of the Netherlands［J］. Acta Neuropsychiatr, 2014,26（3）:186⁃192. doi: 10.1017/neu.2013.53.
［2］	Quintero⁃Moreno JF, Valencia⁃Vasquez A, Aguirre⁃Castaneda C. Clinical and socio⁃demographic profile of neurosyphilis: a retrospective study in a reference centre in Colombia［J］. Rev Neurol, 2019,69（2）:53⁃58. doi: 10.33588/rn.6902.2018381.
［3］	Lu Y, Ke W, Yang L, et al. Clinical prediction and diagnosis of neurosyphilis in HIV⁃negative patients: a case⁃control study［J］. BMC Infect Dis, 2019,19（1）:1017. doi: 10.1186/s12879⁃019⁃4582⁃2.
［4］	Shi M, Peng RR, Gao Z, et al. Risk profiles of neurosyphilis in HIV⁃negative patients with primary, secondary and latent syphilis: implications for clinical intervention［J］. J Eur Acad Dermatol Venereol, 2016,30（4）:659⁃666. doi: 10.1111/jdv.13514.
［5］	Li W, Jiang M, Xu D, et al. Clinical and laboratory characteristics of symptomatic and asymptomatic neurosyphilis in HIV⁃negative patients: a retrospective study of 264 cases［J］. Biomed Res Int, 2019,2019:2426313. doi: 10.1155/2019/2426313.
［6］	Cai SN, Long J, Chen C, et al. Incidence of asymptomatic neurosyphilis in serofast Chinese syphilis patients［J］. Sci Rep, 2017,7（1）:15456. doi: 10.1038/s41598⁃017⁃15641⁃w.
［7］	Landry T, Smyczek P, Cooper R, et al. Retrospective review of tertiary and neurosyphilis cases in Alberta, 1973⁃2017［J］. BMJ Open, 2019,9（6）:e025995. doi: 10.1136/bmjopen⁃2018⁃025995.
［8］	de Voux A, Kidd S, Torrone EA. Reported cases of neurosyphilis among early syphilis cases⁃United States, 2009 to 2015［J］. Sex Transm Dis, 2018,45（1）:39⁃41. doi: 10.1097/OLQ.0000000 000000687.
［9］	Hagihara M, Yamagishi Y, Kato H, et al. Frequency of Treponema pallidum invasion into cerebrospinal fluid in primary or secondary early⁃stage syphilis［J］. J Infect Chemother, 2018,24（5）:404⁃406. doi: 10.1016/j.jiac.2017.11.007.
［10］	Zhou P, Gu X, Lu H, et al. Re⁃evaluation of serological criteria for early syphilis treatment efficacy: progression to neurosyphilis despite therapy［J］. Sex Transm Infect, 2012,88（5）:342⁃345. doi: 10.1136/sextrans⁃2011⁃050247.
［11］	Ropper AH. Neurosyphilis［J］. N Engl J Med, 2019,381（14）:1358⁃1363. doi: 10.1056/NEJMra1906228.
［12］	Tomkins A, Ahmad S, Cousins DE, et al. Screening for asymptomatic neurosyphilis in HIV patients after treatment of early syphilis: an observational study［J］. Sex Transm Infect, 2018,94（5）:337⁃339. doi: 10.1136/sextrans⁃2016⁃052938.
［13］	Marra CM, Maxwell CL, Dunaway SB, et al. Cerebrospinal fluid Treponema pallidum particle agglutination assay for neurosyphilis diagnosis［J］. J Clin Microbiol, 2017,55（6）:1865⁃1870. doi: 10.1128/JCM.00310⁃17.
［14］	曹珊珊, 李红阳, 徐全刚, 等. 以视神经炎为首发的神经梅毒的临床观察［J］. 中华眼科杂志, 2016,52（12）:898⁃904. doi: 10.3760/cma.j.issn.0412⁃4081.2016.12.006.
［15］	Jiang Y, Weng R, Zhang Y, et al. The performance of rapid plasma reagin （RPR） titer in HIV⁃negative general paresis after neurosyphilis therapy［J］. BMC Infect Dis, 2018,18（1）:144. doi: 10.1186/s12879⁃018⁃3062⁃4.
［16］	Xiao Y, Tong ML, Liu LL, et al. Novel predictors of neurosyphilis among HIV⁃negative syphilis patients with neurological symptoms: an observational study［J］. BMC Infect Dis, 2017,17（1）:310. doi: 10.1186/s12879⁃017⁃2339⁃3.
［17］	Smibert OC, Abbinga S, Spelman DW, et al. Neurosyphilis: concordance between cerebrospinal fluid analysis and subsequent antibiotic strategy for patients undergoing evaluation of a diagnosis of neurosyphilis［J］. Int J Infect Dis, 2019,82:73⁃76. doi: 10.1016/j.ijid.2019.03.003.
［18］	Shiva F, Goldmeier D, Lane P, et al. Cerebrospinal fluid TPPA titres in the diagnosis of neurosyphilis［J］. Sex Transm Infect, 2020. doi: 10.1136/sextrans⁃2019⁃054198.
［19］	Dombrowski JC, Pedersen R, Marra CM, et al. Prevalence estimates of complicated syphilis［J］. Sex Transm Dis, 2015,42（12）:702⁃704. doi: 10.1097/OLQ.0000000000000368.
［20］	Bazewicz M, Lhoir S, Makhoul D, et al. Neurosyphilis cerebrospinal fluid findings in patients with ocular syphilis［J］. Ocul Immunol Inflamm, 2019:1⁃7. doi: 10.1080/09273948.2019. 1672193.
［21］	Singh AE. Ocular and neurosyphilis: epidemiology and approach to management［J］. Curr Opin Infect Dis, 2020,33（1）:66⁃72. doi: 10.1097/QCO.0000000000000617.
［22］	An Q, Wejnert C, Bernstein K, et al. Syphilis screening and diagnosis among men who have sex with men, 2008⁃2014, 20 U.S. Cities［J］. J Acquir Immune Defic Syndr, 2017,75 Suppl 3:S363⁃S369. doi: 10.1097/QAI.0000000000001412.
［23］	Rotman L, Luo X, Thompson A, et al. Risk of neurosyphilis in HIV⁃infected persons with syphilis lacking signs or symptoms of central nervous system infection［J］. HIV Med, 2019,20（1）:27⁃32. doi: 10.1111/hiv.12677.
［24］	Salado⁃Rasmussen K, Wessman M, Cowan SA, et al. Syphilitic hepatitis and neurosyphilis: an observational study of Danish HIV⁃infected individuals during a 13⁃year period［J］. Sex Transm Infect, 2019,95（6）:416⁃418. doi: 10.1136/sextrans⁃2018⁃053921.
［25］	Mathew D, Smit D. Clinical and laboratory characteristics of ocular syphilis and neurosyphilis among individuals with and without HIV infection［J］. Br J Ophthalmol, 2020. doi: 10.1136/bjophthalmol⁃2019⁃315699.
［26］	Firlag⁃Burkacka E, Swiecki P, Cielniak I, et al. High frequency of neurosyphilis in HIV⁃positive patients diagnosed with early syphilis［J］. HIV Med, 2016,17（5）:323⁃326. doi: 10.1111/hiv. 12307.
［27］	Wang YJ, Chi CY, Chou CH, et al. Syphilis and neurosyphilis in human immunodeficiency virus⁃infected patients: a retrospective study at a teaching hospital in Taiwan［J］. J Microbiol Immunol Infect, 2012,45（5）:337⁃342. doi: 10.1016/j.jmii.2011.12.011.
［28］	Sun JJ, Wang ZY, Shen JY, et al. Serum TRSUT titer ≥1: 16 is a predictor for neurosyphilis among HIV⁃infected patients with concurrent syphilis and no neurological symptoms［J］. Medicine （Baltimore）, 2015,94（45）:e2023. doi: 10.1097/MD.0000000000 002023.
［29］	Poliseli R, Vidal JE, Penalva De Oliveira AC, et al. Neurosyphilis in HIV⁃infected patients: clinical manifestations, serum venereal disease research laboratory titers, and associated factors to symptomatic neurosyphilis［J］. Sex Transm Dis, 2008,35（5）:425⁃429. doi: 10.1097/OLQ.0b013e3181623853.
［30］	Flood JM, Weinstock HS, Guroy ME, et al. Neurosyphilis during the AIDS epidemic, San Francisco, 1985⁃1992［J］. J Infect Dis, 1998,177（4）:931⁃940. doi: 10.1086/515245.
［31］	Pastuszczak M, Sitko M, Bociaga⁃Jasik M, et al. Lack of antiretroviral therapy is associated with higher risk of neurosyphilis among HIV⁃infected patients who remain serofast after therapy for early syphilis［J］. Medicine （Baltimore）, 2018,97（45）:e13171. doi: 10.1097/MD.0000000000013171.
［32］	Dumaresq J, Langevin S, Gagnon S, et al. Clinical prediction and diagnosis of neurosyphilis in HIV⁃infected patients with early Syphilis［J］. J Clin Microbiol, 2013,51（12）:4060⁃4066. doi: 10. 1128/JCM.01989⁃13.
［33］	Wang Z, Liu L, Shen YZ, et al. The clinical and laboratory features of neurosyphilis in HIV⁃infected patients: a retrospective study in 92 patients［J］. Medicine （Baltimore）, 2018,97（9）:e0078. doi: 10.1097/MD.0000000000010078.
［34］	Davis AP, Stern J, Tantalo L, et al. How well do neurologic symptoms identify individuals with neurosyphilis?［J］. Clin Infect Dis, 2018,66（3）:363⁃367. doi: 10.1093/cid/cix799.

[1]	孙祖凤陈京京朱虹周敏温志华顾宁琰张宇姚煦. 糖皮质激素治疗的天疱疮患者骨质疏松现状分析[J]. 中华皮肤科杂志, 2020, 53(4): 296-298.
[2]	付玉姣郭静史娜娜宁心强韦芳林郑艳青郑冬燕曹存巍. 抗γ干扰素自身抗体阳性伴Sweet综合征的马尔尼菲篮状菌病九例临床分析[J]. 中华皮肤科杂志, 2020, 53(2): 109-112.
[3]	汤华阳高金平郭泽魏瑾樊娇娇唐先发王培光孔晓明杨森. 131例神经梅毒患者临床特征及实验室检查结果分析[J]. 中华皮肤科杂志, 2020, 53(10): 774-780.
[4]	郑国霞刘如锦齐燕王小波闫玉涛谭晓华杨磊. 病毒巨噬细胞炎症蛋白Ⅱ对293T细胞APOBEC3G表达的影响[J]. 中华皮肤科杂志, 2019, 52(9): 624-630.
[5]	吴凡胡文龙许卜方王千秋. 梅毒螺旋体对人脑微血管内皮细胞趋化因子配体6、8、10表达的影响[J]. 中华皮肤科杂志, 2018, 51(5): 358-362.
[6]	刘文邓美霞张晓红赵铁罗茜赵飞骏尹卫国. 梅毒螺旋体体内诱生抗原Tp0462的表达鉴定及在临床血清学诊断中的应用评价[J]. 中华皮肤科杂志, 2018, 51(5): 352-357.
[7]	韩燕魏万惠尹跃平 David Anderson 王红春 Mary L Gacia Huy Van 朱小宇陈凯陈祥生. 梅毒IgA快速检测试剂诊断早期现症梅毒的应用性评估[J]. 中华皮肤科杂志, 2018, 51(5): 372-375.
[8]	华优王敏高亚丽耿清伟相文忠宋秀祖. 糖皮质激素诱发类固醇糖尿病38例临床分析[J]. 中华皮肤科杂志, 2018, 51(4): 269-273.
[9]	王娜蒋法兴朱文兰倩. 非梅毒螺旋体血清学试验持续阳性梅毒患者神经梅毒发生情况及影响因素分析[J]. 中华皮肤科杂志, 2016, 49(5): 314-317.
[10]	杨庆伟杨家外景正朝. 麻风病合并HIV感染一例[J]. 中华皮肤科杂志, 2014, 47(8): 562-562.
[11]	徐建荣季必华秦其荣丁以星夏福林. 马鞍山市吸毒者美沙酮维持期间梅毒血清阳转及危险因素的研究[J]. 中华皮肤科杂志, 2014, 47(5): 351-353.
[12]	刘蔚胡白赵政龙张思平蒋法兴刘琼. 播散性带状疱疹76例临床分析[J]. 中华皮肤科杂志, 2014, 47(1): 38-41.
[13]	李湘辉阳芳黄少锋鲁东平张荣邓宝清. 梅毒孕妇分娩的新生儿血清学随访[J]. 中华皮肤科杂志, 2012, 45(12): 851-854.
[14]	卢良君许爱娥关翠萍陈梅花. 白癜风进展相关危险因素分析[J]. 中华皮肤科杂志, 2011, 44(1): 52-54.
[15]	蒋法兴胡白汤其强赵政龙吴爱丽张思平廖理超刘金丽周海林王千秋. 18例神经梅毒临床分析[J]. 中华皮肤科杂志, 2010, 43(5): 301-304.